4.5 Article

COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention

Journal

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 19, Issue 9, Pages 1083-1092

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2021.1893692

Keywords

Cytokine storm; Pneumocytes; Cardiotoxicity; NLRP3 inflammasome and COVID-19

Ask authors/readers for more resources

The novel coronavirus has been associated with severe acute respiratory distress syndrome (ARDS) and notable cardiovascular complications. Proposed mechanisms of cardiovascular complications include virus infection, cytokine storm, altered immune response, and myocardial tissue damage. Monitoring risk-benefit ratio of treatment paradigm and cardiac injury biomarkers regularly is crucial for COVID-19 patients, along with potential clinical trials comparing anti-COVID-19 drugs with cardioprotective anti-inflammatory drugs. Vaccines are the ideal solution, but in the meantime, sanitization, social distancing, and a healthy lifestyle are key in combating the global pandemic.
Introduction: The novel coronavirus has caused significant mortality worldwide and is primarily associated with severe acute respiratory distress syndrome (ARDS). Apart from ARDS, clinical reports have shown noticeable cardiovascular complications among the patients of COVID-19. Infection from virus, stimulation of cytokine storm, altered immune response, and damage to myocardial tissue are some of the proposed mechanisms of cardiovascular complications in COVID-19. Areas covered: Based on the clinical reports of CVDs among COVID-19 patients, we have discussed the molecular mechanisms involved in cardiovascular pathogenesis, its prevalence, and association with COVID-19, and various available therapeutic modality for the treatment. Expert opinion: Seeing the cardiovascular complications in COVID-19 patients and its association with the existing drug, risk-benefit ratio of treatment paradigm, as well as the level of cardiac injury biomarkers must be monitored regularly. Additionally, a well-designed clinical trial should be conducted where head to head comparison can be made with anti-COVID-19 drugs and cardioprotective anti-inflammatory drugs. Nevertheless, vaccines are the best-suited approach, but until then, sanitization, social distancing, and active lifestyle are the best ways to beat this global pandemic situation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available